ticagrelor | sciencenewsnet.in

Breaking News

Structural Safety Monitoring of Buildings with Color Variations

Out of Africa: UT Southwestern cardiologist gets to the heart of Zambia’s No. 1 health threat

Weight loss interventions associated with improvements in several symptoms of PCOS

Policies assuring safe practice by late-career physicians vary widely among health care organizations

Researchers report first published case of a patient with treatment-emergent neuroendocrine prostate cancer who showed a remarkable response to an anti-HER2 antibody-drug conjugate

Patients outside metropolitan areas often travel significantly more than 20 minutes for primary care visit

Discovery of a protein’s key role in RNA processes could improve disease treatment in humans and plants

Health Research Launches Into Orbit to Discover How Spaceflight Affects Blood

Argonne to help drive AI revolution in astronomy with new institute led by Northwestern University

Gastrointestinal Surgeon Fabrizio Michelassi, MD, FACS, Elected Chair of ACS Board of Regents

05 Nov, 2024

Ticagrelor Without Aspirin Three Months After Successful PCI and DAPT Reduces Major Bleeding Without Increasing the Risk of Adverse Events

September 26, 2019 sarah JonasResearch Results

New data from the randomized, placebo-controlled TWILIGHT trial found that compared to ticagrelor plus aspirin, ticagrelor monotherapy reduces bleeding events without increasing the risk of death, myocardial infarction, or stroke in high-risk patients who have undergone successful percutaneous coronary intervention (PCI) and completed three months of dual antiplatelet therapy (DAPT).